

Brand Name: Delstrigo

Generic: doravirine/lamivudine/tenofovir DF

Type: small molecule

Year Accepted/Phase: 2018


Mechanism:

Doravirine: Inhibits HIV-1 reverse transcriptase by binding to a different site than NRTIs, leading to inhibition of viral replication.


Lamivudine and Tenofovir DF: Both are NRTIs that incorporate into viral DNA and cause chain termination during reverse transcription.

Chemical Structure:


doravirine



lamivudine



tenofovir disoproxil



Indication:

Delstrigo is indicated for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment history.

Clinical trials:

DRIVE-AHEAD Trial (Phase III)

Pubmed: <https://pubmed.ncbi.nlm.nih.gov/33336698/>

Purpose: Evaluate the efficacy and safety of doravirine/lamivudine/tenofovir DF compared to efavirenz/emtricitabine/tenofovir DF in treatment-naïve adults with HIV-1 infection.

Dates: Conducted from 2014 to 2017.

Results: The DRIVE-AHEAD trial demonstrated that doravirine/lamivudine/tenofovir DF was non-inferior to efavirenz/emtricitabine/tenofovir DF in achieving viral suppression at 48 weeks. The incidence of neuropsychiatric adverse events was lower in the doravirine/lamivudine/tenofovir DF group.

Impact: The trial supported the use of Delstrigo as an effective and well-tolerated option for first-line treatment of HIV-1 infection.

DRIVE-FORWARD Trial (Phase III)

Pubmed: <https://pubmed.ncbi.nlm.nih.gov/31740348/>

Purpose: Evaluate the efficacy and safety of doravirine compared to darunavir/ritonavir in combination with other antiretroviral drugs in treatment-experienced adults with HIV-1 infection.

Dates: Conducted from 2014 to 2017.

Results: The DRIVE-FORWARD trial showed that doravirine was non-inferior to darunavir/ritonavir in achieving viral suppression at 48 weeks. Patients in the doravirine group had fewer treatment-related adverse events.

Impact: These results further established the efficacy and safety profile of doravirine as a component of antiretroviral therapy.